SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
Open Access
- 15 April 2022
- journal article
- research article
- Published by Elsevier BV in Cell Reports
- Vol. 39 (5), 110754
- https://doi.org/10.1016/j.celrep.2022.110754
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2020
- SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2Cell, 2020
- Distinct conformational states of SARS-CoV-2 spike proteinScience, 2020
- Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein VariantCell, 2020
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktailScience, 2020
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 VirusCell, 2020
- A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2Nature, 2020
- Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated NeutralizationJournal of Virology, 2019
- The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cellsPLOS ONE, 2017
- A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I InterferonPLOS ONE, 2011